The New Process Validation Paradigm - Ispe Bost... (Trusted)

The focus here is on building a deep understanding of the product and process. By identifying Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) early on, manufacturers can establish a "Design Space" where quality is guaranteed through scientific rationale rather than luck.

The New Process Validation Paradigm represents a move toward a more "proactive" pharmaceutical quality system. By treating validation as an ongoing journey rather than a destination, the industry ensures a more reliable supply of safe, effective medicines for patients.

Perhaps the most critical shift, CPV requires ongoing monitoring during routine production. By using statistical process control (SPC), manufacturers can detect drifts or trends before they lead to failures, ensuring the process remains in a state of control throughout its entire commercial life. Why It Matters The New Process Validation Paradigm - ISPE Bost...

This stage replaces the rigid "three-batch" rule. Instead, the number of batches is determined by risk assessment and statistical confidence. It confirms that the process design is capable of reproducible commercial manufacturing.

It aligns with ICH Q8, Q9, and Q10 guidelines, facilitating smoother inspections and global compliance. Conclusion The focus here is on building a deep

Early identification of variability prevents costly batch failures.

The new paradigm is structured into three distinct stages that move away from static documentation toward continuous learning: By treating validation as an ongoing journey rather

This shift from "snapshots" to "continuous oversight" offers significant benefits: